HK1109594A1 - Improved quenching methods for red blood cell inactivation process - Google Patents

Improved quenching methods for red blood cell inactivation process

Info

Publication number
HK1109594A1
HK1109594A1 HK08103739.2A HK08103739A HK1109594A1 HK 1109594 A1 HK1109594 A1 HK 1109594A1 HK 08103739 A HK08103739 A HK 08103739A HK 1109594 A1 HK1109594 A1 HK 1109594A1
Authority
HK
Hong Kong
Prior art keywords
red blood
blood cell
methods
improved
quencher
Prior art date
Application number
HK08103739.2A
Other languages
English (en)
Inventor
Adonis Stassinopoulos
Original Assignee
Cerus Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cerus Corp filed Critical Cerus Corp
Publication of HK1109594A1 publication Critical patent/HK1109594A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
    • A61L2/0082—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using chemical substances
    • A61L2/0088—Liquid substances
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/02—Preservation of living parts
    • A01N1/0205—Chemical aspects
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/02—Preservation of living parts
    • A01N1/0205—Chemical aspects
    • A01N1/021—Preservation or perfusion media, liquids, solids or gases used in the preservation of cells, tissue, organs or bodily fluids
    • A01N1/0215—Disinfecting agents, e.g. antimicrobials for preserving living parts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Environmental Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Dentistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK08103739.2A 2004-10-29 2008-04-02 Improved quenching methods for red blood cell inactivation process HK1109594A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62317704P 2004-10-29 2004-10-29
PCT/US2005/039392 WO2006050328A1 (en) 2004-10-29 2005-10-31 Improved quenching methods for red blood cell inactivation process

Publications (1)

Publication Number Publication Date
HK1109594A1 true HK1109594A1 (en) 2008-06-13

Family

ID=35789172

Family Applications (1)

Application Number Title Priority Date Filing Date
HK08103739.2A HK1109594A1 (en) 2004-10-29 2008-04-02 Improved quenching methods for red blood cell inactivation process

Country Status (13)

Country Link
US (1) US7655392B2 (pl)
EP (1) EP1838355B1 (pl)
JP (3) JP5346468B2 (pl)
CN (2) CN101094692A (pl)
AU (2) AU2005302256B2 (pl)
BR (1) BRPI0518198B8 (pl)
CA (1) CA2585621C (pl)
DK (1) DK1838355T3 (pl)
ES (1) ES2429088T3 (pl)
HK (1) HK1109594A1 (pl)
PL (1) PL1838355T3 (pl)
PT (1) PT1838355E (pl)
WO (1) WO2006050328A1 (pl)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU745209B2 (en) * 1998-01-06 2002-03-14 Cerus Corporation Methods for quenching pathogen inactivators in biological materials
US7655392B2 (en) 2004-10-29 2010-02-02 Cerus Corporation Quenching methods for red blood cell inactivation process
ES2636563T3 (es) * 2008-04-09 2017-10-06 Cerus Corporation Método de reducción de la deshidratación en una composición de glóbulos rojos
US12089589B2 (en) 2009-10-12 2024-09-17 Hemanext Inc. Irradiation of red blood cells and anaerobic storage
US11284616B2 (en) 2010-05-05 2022-03-29 Hemanext Inc. Irradiation of red blood cells and anaerobic storage
US9199016B2 (en) 2009-10-12 2015-12-01 New Health Sciences, Inc. System for extended storage of red blood cells and methods of use
US7989593B1 (en) 2010-05-27 2011-08-02 Bing Lou Wong Method for the preparation of a high-temperature stable oxygen-carrier-containing pharmaceutical composition and the use thereof
US8048856B1 (en) 2010-06-23 2011-11-01 Billion King, Ltd. Treatment methods using a heat stable oxygen carrier-containing pharmaceutical composition
US7932356B1 (en) 2010-06-23 2011-04-26 Bing Lou Wong Method for the preparation of a heat stable oxygen carrier-containing pharmaceutical composition
US8084581B1 (en) 2011-04-29 2011-12-27 Bing Lou Wong Method for removing unmodified hemoglobin from cross-linked hemoglobin solutions including polymeric hemoglobin with a high temperature short time heat treatment apparatus
US20130052232A1 (en) 2011-08-31 2013-02-28 Bing Lou Wong Method for the preparation of a heat stable oxygen carrier-containing composition facilating beta-beta cross-linking
US20160081328A1 (en) * 2013-05-10 2016-03-24 President And Fellows Of Harvard College Solutions for Red Blood Cells
WO2016014854A1 (en) 2014-07-23 2016-01-28 Cerus Corporation Methods for preparing platelet products
WO2016145210A1 (en) 2015-03-10 2016-09-15 New Health Sciences, Inc. Oxygen reduction disposable kits, devices and methods of use thereof
KR20240067253A (ko) 2015-04-23 2024-05-16 헤마넥스트 인코포레이티드 혐기성 혈액 저장 용기
AU2016264327B2 (en) 2015-05-18 2021-12-23 Hemanext Inc. Methods for the storage of whole blood, and compositions thereof
US11096963B2 (en) 2015-06-26 2021-08-24 Cerus Corporation Cryoprecipitate compositions and methods of preparation thereof
EP3364986B1 (en) 2015-10-23 2023-12-13 Cerus Corporation Pathogen-inactivated cryo-poor plasma and methods of use thereof
IL303240A (en) 2016-05-27 2023-07-01 Hemanext Inc Anaerobic blood storage and pathogen inactivation method
JP2020503512A (ja) * 2016-12-23 2020-01-30 シーラス コーポレイション 化合物結合基材を使用して、試験およびスクリーニングするためのシステムおよび方法
US20190321407A1 (en) * 2016-12-31 2019-10-24 Cerus Corporation Compositions and methods for preparation of red blood cells
BR112019018273A2 (pt) 2017-03-03 2020-07-14 Cerus Corporation kits e métodos para preparação de composições de plaquetas inativadas por patógenos
KR20200088801A (ko) 2017-09-20 2020-07-23 세루스 코포레이션 혈소판의 병원체 비활성화를 위한 조성물 및 방법
IL275698B2 (en) 2017-12-29 2024-08-01 Cerus Corp Systems and methods for treating biological fluids
CA3107314A1 (en) * 2018-07-27 2020-01-30 Zata Pharmaceuticals, Inc. Method for pathogens, microorganisms, and parasites inactivation
IL281504B2 (en) * 2018-09-20 2024-08-01 Cerus Corp Methods and kits for preparing pathogen-neutralized whole blood
US12011510B2 (en) 2019-06-22 2024-06-18 Cerus Corporation Biological fluid treatment systems
AU2020308035A1 (en) 2019-06-28 2022-02-17 Cerus Corporation System and methods for implementing a biological fluid treatment device
EP4240757A2 (en) 2020-11-09 2023-09-13 Takeda Pharmaceutical Company Limited Purification of fviii from plasma using silicon oxide adsorption

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2402665A (en) * 1942-11-12 1946-06-25 Du Pont Chemical process
IT1093275B (it) * 1978-01-26 1985-07-19 Snam Progetti Composizione adatta alla purificazione del sangue e suoi impieghi
US4337269A (en) * 1979-07-23 1982-06-29 Sutton Laboratories, Inc. Preservative compositions
US4727027A (en) * 1983-05-02 1988-02-23 Diamond Scientific Co. Photochemical decontamination treatment of whole blood or blood components
US4748120A (en) * 1983-05-02 1988-05-31 Diamond Scientific Co. Photochemical decontamination treatment of whole blood or blood components
US5281579A (en) * 1984-03-23 1994-01-25 Baxter International Inc. Purified virus-free hemoglobin solutions and method for making same
US4971760A (en) * 1986-03-10 1990-11-20 University Of Southern California Novel method for disinfecting red blood cells, blood platelets, blood plasma, and optical corneas and sclerae
US4944920A (en) * 1986-08-01 1990-07-31 University Of Southern California Novel method to treat blood
US4920143A (en) 1987-04-23 1990-04-24 University Of British Columbia Hydro-monobenzoporphyrin wavelength-specific cytotoxic agents
US5094960A (en) * 1988-10-07 1992-03-10 New York Blood Center, Inc. Removal of process chemicals from labile biological mixtures by hydrophobic interaction chromatography
US5055485A (en) * 1988-12-02 1991-10-08 New York Blood Center, Inc. Inactivation of viruses in cell- and protein-containing compositions using aryl diol epoxides
US5587490A (en) * 1990-04-16 1996-12-24 Credit Managers Association Of California Method of inactivation of viral and bacterial blood contaminants
US5418130A (en) * 1990-04-16 1995-05-23 Cryopharm Corporation Method of inactivation of viral and bacterial blood contaminants
US5120649A (en) * 1990-05-15 1992-06-09 New York Blood Center, Inc. Photodynamic inactivation of viruses in blood cell-containing compositions
US5232844A (en) * 1990-05-15 1993-08-03 New York Blood Center Photodynamic inactivation of viruses in cell-containing compositions
US5658722A (en) * 1990-05-15 1997-08-19 New York Blood Center, Inc. Process for the sterilization of biological compositions using UVA1 irradiation
US5753258A (en) * 1990-10-19 1998-05-19 University Of Florida Artificial viral envelopes
GB9218581D0 (en) * 1992-09-02 1992-10-14 Pall Corp Removal of unwanted fluids from processed blood products
WO1995000631A1 (en) 1993-06-23 1995-01-05 New York Blood Center, Inc. System for viral inactivation of blood
US5591350A (en) * 1994-04-15 1997-01-07 Pall Corporation Iodine disinfection method using a gaseous iodine treated porous medium
SE9402472L (sv) 1994-07-13 1996-01-14 Forskarpatent I Linkoeping Ab Modifierade ytor
US5522385A (en) 1994-09-27 1996-06-04 Aradigm Corporation Dynamic particle size control for aerosolized drug delivery
US5660731A (en) * 1994-11-08 1997-08-26 Pall Corporation Filter for separating photoactive agent
US5691132A (en) * 1994-11-14 1997-11-25 Cerus Corporation Method for inactivating pathogens in red cell compositions using quinacrine mustard
US5637451A (en) * 1995-03-29 1997-06-10 New York Blood Center, Inc. Photodynamic treatment of red blood cells with phthalocyanines and red light at higher light fluence rates is protective of red blood cells
US6177441B1 (en) * 1995-06-05 2001-01-23 Cerus Corporation Treating red blood cell solutions with anti-viral agents
AU722811B2 (en) 1995-06-07 2000-08-10 Cerus Corporation Treating red blood cell solutions with anti-viral agents
ES2337852T3 (es) 1995-06-07 2010-04-29 Cerus Corporation Metodos y dispositivos para la eliminacion de psoralenos de productos sanguineos.
US20020192632A1 (en) * 1995-06-07 2002-12-19 Hei Derek J. Method and devices for the removal of psoralens from blood products
WO1996039816A1 (en) 1995-06-07 1996-12-19 Baxter International Inc. Method of inactivation of viral and bacterial blood contaminants
US6544727B1 (en) * 1995-06-07 2003-04-08 Cerus Corporation Methods and devices for the removal of psoralens from blood products
WO1997002028A1 (en) 1995-06-29 1997-01-23 Hemasure, Inc. Inactivation of pathogens using hydroxymethylamines
US6114108A (en) 1995-08-29 2000-09-05 V.I. Technologies, Inc. Methods and compositions for the selective modification of viral nucleic acids
US6136586A (en) * 1995-08-29 2000-10-24 Vi Technologies, Inc. Methods for the selective modification of viral nucleic acids
JP2000500137A (ja) 1995-11-06 2000-01-11 ニューヨーク・ブラッド・センター・インコーポレイテッド フタロシアニン及び赤色光を用いた赤血球細胞のウイルス不活性化処理
AU1085697A (en) 1995-11-21 1997-06-11 Pall Corporation Inactivation method and system in biological fluids
ES2196530T3 (es) 1997-01-06 2003-12-16 Cerus Corp Compuestos de ruptura para inactivar patogenos.
US20010018179A1 (en) * 1998-01-06 2001-08-30 Derek J. Hei Batch devices for the reduction of compounds from biological compositions containing cells and methods of use
US6514987B1 (en) * 1997-01-06 2003-02-04 Cerus Corporation Frangible compounds for pathogen inactivation
US20010009756A1 (en) * 1998-01-06 2001-07-26 Derek Hei Flow devices for the reduction of compounds from biological compositions and methods of use
US6093725A (en) * 1997-01-06 2000-07-25 Cerus Corporation Frangible compounds for pathogen inactivation
US6093564A (en) * 1997-10-03 2000-07-25 V.I. Technologies, Inc. Methods and compositions for the selective modification of nucleic acids
AU745209B2 (en) * 1998-01-06 2002-03-14 Cerus Corporation Methods for quenching pathogen inactivators in biological materials
US6277337B1 (en) * 1998-07-21 2001-08-21 Gambro, Inc. Method and apparatus for inactivation of biological contaminants using photosensitizers
US6150109A (en) * 1999-01-25 2000-11-21 V. I. TECHNOLOGIES, Inc. Lipophilic quenching of viral inactivating agents
EP1284743A2 (en) * 2000-05-31 2003-02-26 Cerus Corporation Preparation of a pathogen inactivated solution of red blood cells having reduced immunogenicity
CN100417325C (zh) * 2000-11-04 2008-09-10 王祥文 卫生灭菌消毒剂
CA2434256A1 (en) * 2000-12-21 2003-07-31 David Cook Methods for inactivation of pathogens in biological materials
CN1186099C (zh) * 2001-12-13 2005-01-26 孙岩军 麻醉机呼吸回路清洗消毒的方法及其操作步骤
US7655392B2 (en) 2004-10-29 2010-02-02 Cerus Corporation Quenching methods for red blood cell inactivation process

Also Published As

Publication number Publication date
EP1838355A1 (en) 2007-10-03
CN103961731B (zh) 2017-01-18
ES2429088T3 (es) 2013-11-13
AU2005302256B2 (en) 2011-01-20
PL1838355T3 (pl) 2014-01-31
DK1838355T3 (da) 2013-10-28
EP1838355B1 (en) 2013-08-14
US7655392B2 (en) 2010-02-02
JP5346468B2 (ja) 2013-11-20
JP5718840B2 (ja) 2015-05-13
WO2006050328A1 (en) 2006-05-11
BRPI0518198B1 (pt) 2018-11-21
CA2585621A1 (en) 2006-05-11
CN103961731A (zh) 2014-08-06
CN101094692A (zh) 2007-12-26
JP2008518952A (ja) 2008-06-05
PT1838355E (pt) 2013-11-07
AU2011201554B2 (en) 2012-04-26
BRPI0518198A (pt) 2008-11-04
BRPI0518198B8 (pt) 2021-06-22
CA2585621C (en) 2015-12-15
JP2013256537A (ja) 2013-12-26
AU2005302256A1 (en) 2006-05-11
AU2011201554A1 (en) 2011-04-28
US20060115466A1 (en) 2006-06-01
JP2012107068A (ja) 2012-06-07

Similar Documents

Publication Publication Date Title
HK1109594A1 (en) Improved quenching methods for red blood cell inactivation process
DE69826521D1 (de) Verfahren zum quenchen von pathogen-inaktivatoren in biologischen materialien
ATE541053T1 (de) Verfahren und zusammensetzungen zur behandlung von nichtkleinzelligem lungenkrebs
GB2397818A (en) Rna interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid
WO2005078097A3 (en) RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING MULTIFUNCTIONAL SHORT INTERFERING NUCLEIC ACID (Multifunctional siNA)
EA200300947A1 (ru) Арил и гетероарил мочевины в качестве ингибиторов chk1 для использования в качестве радиосенсибилизаторов и химиосенсибилизаторов
WO2004092405A3 (en) Juvenile hemochromatosis gene (hfe2a), expression products and uses thereof
TNSN06059A1 (en) Use of polypeptides of the cupredoxin family in cancer therapy
WO2003000707A3 (en) Antisense modulation of superoxide dismutase 1, soluble expression
WO2002020500A3 (en) Materials and methods to potentiate cancer treatment
WO2005030254A3 (en) Conjugates for photodynamic therapy
GB0417487D0 (en) Organic compound
WO2005062977A3 (en) Prostate cancer specific internalizing human antibodies
ATE415962T1 (de) Verwendung von asiatsäure oder asiaticosid zur behandlung von krebs
WO2004106495A3 (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
WO2001079164A3 (en) N-substituted dithiocarbamates for the treatment of biological disorders
WO2004087965A3 (en) Statistical analysis of regulatory factor binding sites of differentially expressed genes
HK1078593A1 (en) Antibody against a tumor-specific antigen as target
DE602005026811D1 (de) Verfahren zur inhibierung von tumorzellwachstum mit foxm1 sirns
WO2003030725A3 (en) Pancreatic cancer diagnosis and therapies
WO2004009112A8 (en) Use of urease for inhibiting cancer cell growth
WO2004024062A3 (en) Platinum complexes as antitumor agents in combination with biochemical modulation
KOMEYLIZADEH Does nature prefer heterocycles?
WO2003076610A3 (fr) Variants de kallikrein-2 et kallikrein-3 humaines et leurs utilisations
UA93538C2 (en) Aurora kinase modulators and method of use